Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab and Vinorelbine +/- Avelumab +/- Utomilumab in HER2+ Metastatic Breast Cancer
NCT03414658Phase 2Active, not recruiting
- Sponsor
- Adrienne G. Waks
- Start
- Jun 2018
- Primary completion
- May 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of avelumab, utomilumab in breast cancer, sponsored by Adrienne G. Waks. Started Jun 2018; status: active, not recruiting.
02
Drugs
avelumabutomilumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03414658.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03414658.